Tags

Type your tag names separated by a space and hit enter

Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
Arch Pediatr Adolesc Med 2006; 160(1):82-90AP

Abstract

BACKGROUND

Despite the persistence of attention-deficit/hyperactivity disorder (ADHD) into adolescence, little is known about the efficacy and tolerability of stimulant medications in this age group.

OBJECTIVE

To report the results of a multisite controlled study among adolescents with ADHD evaluating the efficacy and tolerability of osmotic-release oral system (OROS) methylphenidate.

DESIGN

Adolescents (N = 220) having a confirmed Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of ADHD underwent dose titration to identify dosages of OROS methylphenidate that improved symptoms to predefined criteria. Subjects successfully completing the dose titration phase (n = 177) (ie, tolerated and responded to treatment and adhered to the protocol) were randomized to receive 2 weeks' treatment with their individualized dosage of OROS methylphenidate (18, 36, 54, or 72 mg once daily) or placebo. Treatment effectiveness was measured using investigator, parent, and adolescent assessments of ADHD.

RESULTS

A significant reduction from baseline in the investigator-rated ADHD Rating Scale, the primary efficacy measure, was found with OROS methylphenidate treatment compared with placebo. Similar findings were noted with parent- and adolescent-report measures. Based on a Clinical Global Impression improvement subscale score of much or very much improved, 52% of subjects in the OROS methylphenidate group improved compared with 31% receiving placebo. Thirty-seven percent of subjects required the maximum dosage of 72 mg/d. The incidence of drug-related adverse events was similar between the 2 study groups.

CONCLUSION

In adolescents, once-daily OROS methylphenidate significantly reduced ADHD symptoms and was well tolerated using dosages up to 72 mg/d.

Authors+Show Affiliations

Pediatric Psychopharmacology Unit, Massachusetts General Hospital, YAW-6-6A, 32 Fruit Street, Boston, MA 02114, USA. twilens@partners.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16389216

Citation

Wilens, Timothy E., et al. "Multisite Controlled Study of OROS Methylphenidate in the Treatment of Adolescents With Attention-deficit/hyperactivity Disorder." Archives of Pediatrics & Adolescent Medicine, vol. 160, no. 1, 2006, pp. 82-90.
Wilens TE, McBurnett K, Bukstein O, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2006;160(1):82-90.
Wilens, T. E., McBurnett, K., Bukstein, O., McGough, J., Greenhill, L., Lerner, M., ... Lynch, J. M. (2006). Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Archives of Pediatrics & Adolescent Medicine, 160(1), pp. 82-90.
Wilens TE, et al. Multisite Controlled Study of OROS Methylphenidate in the Treatment of Adolescents With Attention-deficit/hyperactivity Disorder. Arch Pediatr Adolesc Med. 2006;160(1):82-90. PubMed PMID: 16389216.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. AU - Wilens,Timothy E, AU - McBurnett,Keith, AU - Bukstein,Oscar, AU - McGough,James, AU - Greenhill,Laurence, AU - Lerner,Marc, AU - Stein,Mark A, AU - Conners,C Keith, AU - Duby,John, AU - Newcorn,Jeffrey, AU - Bailey,Charles E, AU - Kratochvil,Christopher J, AU - Coury,Daniel, AU - Casat,Charles, AU - Denisco,Mary Joan C, AU - Halstead,Patricia, AU - Bloom,Leslie, AU - Zimmerman,Brenda A, AU - Gu,Joan, AU - Cooper,Kimberly M, AU - Lynch,Joseph M, PY - 2006/1/4/pubmed PY - 2006/1/27/medline PY - 2006/1/4/entrez SP - 82 EP - 90 JF - Archives of pediatrics & adolescent medicine JO - Arch Pediatr Adolesc Med VL - 160 IS - 1 N2 - BACKGROUND: Despite the persistence of attention-deficit/hyperactivity disorder (ADHD) into adolescence, little is known about the efficacy and tolerability of stimulant medications in this age group. OBJECTIVE: To report the results of a multisite controlled study among adolescents with ADHD evaluating the efficacy and tolerability of osmotic-release oral system (OROS) methylphenidate. DESIGN: Adolescents (N = 220) having a confirmed Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of ADHD underwent dose titration to identify dosages of OROS methylphenidate that improved symptoms to predefined criteria. Subjects successfully completing the dose titration phase (n = 177) (ie, tolerated and responded to treatment and adhered to the protocol) were randomized to receive 2 weeks' treatment with their individualized dosage of OROS methylphenidate (18, 36, 54, or 72 mg once daily) or placebo. Treatment effectiveness was measured using investigator, parent, and adolescent assessments of ADHD. RESULTS: A significant reduction from baseline in the investigator-rated ADHD Rating Scale, the primary efficacy measure, was found with OROS methylphenidate treatment compared with placebo. Similar findings were noted with parent- and adolescent-report measures. Based on a Clinical Global Impression improvement subscale score of much or very much improved, 52% of subjects in the OROS methylphenidate group improved compared with 31% receiving placebo. Thirty-seven percent of subjects required the maximum dosage of 72 mg/d. The incidence of drug-related adverse events was similar between the 2 study groups. CONCLUSION: In adolescents, once-daily OROS methylphenidate significantly reduced ADHD symptoms and was well tolerated using dosages up to 72 mg/d. SN - 1072-4710 UR - https://www.unboundmedicine.com/medline/citation/16389216/Multisite_controlled_study_of_OROS_methylphenidate_in_the_treatment_of_adolescents_with_attention_deficit/hyperactivity_disorder_ L2 - https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/archpedi.160.1.82 DB - PRIME DP - Unbound Medicine ER -